FIXX News and Press, Homology Medicines Inc. From 06/13/22

Homology Medicines (NASDAQ:FIXX) on Monday said that the U.S. Food and Drug Administration (FDA) had lifted a clinical hold on the company's pheNIX gene therapy clinical trial with HMI-102 for adults with phenylketonuria (PKU). FIXX stock +2.8% to $2.21 in premarket trading. PKU is ...

Day One Biopharmaceuticals (DAWN) +81% announces positive initial data from pivotal FIREFLY-1 trial of Tovorafenib (DAY101) in relapsed pediatric low-grade Glioma. Redbox Entertainment (RDBX) +30%. Ekso Bionics Holdings (EKSO) +22% receives FDA clearance to market its EksoNR Robotic...

- Company Increased Risk-Mitigation Strategies, Including a Steroid-Sparing Immunosuppression Regimen - BEDFORD, Mass., June 13, 2022 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today that the U.S. Food and Drug Administration (F...

A group of biotechs focused on gene therapy candidates surged on Tuesday after the FDA posted a favorable review on a β-thalassemia candidate developed by commercial-stage company Bluebird bio (NASDAQ:BLUE) ahead of an AdCom meeting later this week. The data for the marketing applicati...

- Additional Data at ASGCT Annual Meeting Demonstrate Precision of HR-Based Approach with Genome-Wide Integration Assays Confirming On-Target Editing and No Off-Target Events - - New Data from GTx-mAb Platform Support Potential for Targeting Many Complement-Related Disorders...

Homology Medicines press release (NASDAQ:FIXX): Q1 GAAP EPS of $1.59 beats by $1.52. Collaboration revenues for the quarter ended March 31, 2022 were $0.8 million, compared to $29.3 million for the quarter ended March 31, 2021. Collaboration revenues for the three months ended March 31, 2021 ...

- $130 Million in Non-Dilutive Capital Strengthened Financial Position - - Presentations at Upcoming ASGCT Annual Meeting Include First-Time Details of Mechanism of Action of Nuclease-Free Gene Editing Candidate HMI-103 for PKU; Symposium to Feature Lead Principal ...

- Multiple Presentations Feature HMI-103 Phase 1 Investigational Therapy for PKU, Including Genome-Wide Integration Assays to Confirm No Off-Target Editing - - New Data from GTx-mAb Program Support Potential to Target Many Complement-Related Disorders - - Presentatio...

BEDFORD, Mass., April 21, 2022 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today that Albert Seymour, Ph.D., Chief Scientific Officer, has been promoted to President of Homology. In addition to his role as CSO, Dr. Seymour will assume ...

Shares of Homology Medicines  [[FIXX, -11.11%]] fell on Wednesday after Canaccord Genuity cut its price target on the stock to $7 from $19, noting that the clinical hold on the company's pheNIX gene therapy trial of HMI-102 for phenylketonuria may be prolonged. In February, the gene...